loading
Adaptive Biotechnologies Corp stock is traded at $7.14, with a volume of 1.96M. It is up +4.59% in the last 24 hours and down -14.96% over the past month. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$6.83
Open:
$6.9
24h Volume:
1.96M
Relative Volume:
1.03
Market Cap:
$1.15B
Revenue:
$177.28M
Net Income/Loss:
$-195.24M
P/E Ratio:
-5.3284
EPS:
-1.34
Net Cash Flow:
$-114.54M
1W Performance:
-7.70%
1M Performance:
-14.96%
6M Performance:
+51.99%
1Y Performance:
+184.61%
1-Day Range:
Value
$6.90
$7.19
1-Week Range:
Value
$6.7747
$7.73
52-Week Range:
Value
$2.45
$9.01

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Name
Name
Adaptive Biotechnologies Corp
Name
Phone
206-659-0067
Name
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Name
Employee
619
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
ADPT's Discussions on Twitter

Compare ADPT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ADPT
Adaptive Biotechnologies Corp
7.135 1.15B 177.28M -195.24M -114.54M -1.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.69 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
583.23 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.69 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.00 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.09 26.16B 3.81B -644.79M -669.77M -6.24

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-21-25 Upgrade Goldman Neutral → Buy
Jul-05-23 Resumed JP Morgan Overweight
Jan-05-23 Initiated Scotiabank Sector Outperform
Dec-21-22 Upgrade Piper Sandler Neutral → Overweight
Aug-25-22 Initiated Credit Suisse Underperform
Jun-03-22 Initiated Piper Sandler Neutral
Feb-16-22 Reiterated BTIG Research Buy
Feb-16-22 Reiterated BofA Securities Buy
Feb-16-22 Reiterated Goldman Neutral
Feb-16-22 Reiterated JP Morgan Overweight
Oct-15-21 Resumed Cowen Outperform
Mar-03-21 Downgrade Goldman Buy → Neutral
Oct-08-20 Resumed BTIG Research Buy
Sep-09-20 Initiated Morgan Stanley Equal-Weight
Jun-03-20 Initiated Goldman Buy
Jul-23-19 Initiated BTIG Research Buy
Jul-22-19 Initiated BofA/Merrill Buy
Jul-22-19 Initiated Cowen Outperform
Jul-22-19 Initiated Goldman Neutral
Jul-22-19 Initiated Guggenheim Buy
Jul-22-19 Initiated William Blair Outperform
View All

Adaptive Biotechnologies Corp Stock (ADPT) Latest News

pulisher
05:30 AM

Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket - Benzinga

05:30 AM
pulisher
Apr 21, 2025

Insider ROBINS HARLAN S sells 1,698 of Adaptive Biotechnologies Corp [ADPT] Stock - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

JPMorgan Chase & Co. Lowers Stock Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World

Apr 21, 2025
pulisher
Apr 20, 2025

Alliancebernstein L.P. Sells 1,890 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World

Apr 20, 2025
pulisher
Apr 20, 2025

Federated Hermes Inc. Reduces Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World

Apr 20, 2025
pulisher
Apr 18, 2025

Franklin Resources Inc. Invests $443,000 in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World

Apr 18, 2025
pulisher
Apr 11, 2025

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 | ADPT Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Corebridge Financial Inc. Has $345,000 Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 - The Manila Times

Apr 10, 2025
pulisher
Apr 09, 2025

25,800 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Acquired by KLP Kapitalforvaltning AS - Defense World

Apr 09, 2025
pulisher
Apr 08, 2025

Adaptive Biotechnologies' Mantle Cell Lymphoma Test Receives Expanded Medicare Coverage - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma - The Manila Times

Apr 08, 2025
pulisher
Apr 08, 2025

Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.

Apr 08, 2025
pulisher
Apr 04, 2025

Guess, Tesla, Nvidia And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga

Apr 04, 2025
pulisher
Apr 04, 2025

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga

Apr 04, 2025
pulisher
Apr 02, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Apr 02, 2025
pulisher
Mar 30, 2025

Swiss National Bank Takes $1.22 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Proficio Capital Partners LLC Takes Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Adaptive Biotechnologies Corp: Analyzing ADPT Stock Trends - investchronicle.com

Mar 28, 2025
pulisher
Mar 28, 2025

Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 12-Month HighShould You Buy? - MarketBeat

Mar 28, 2025
pulisher
Mar 27, 2025

Adaptive Biotechnologies’ chief scientific officer sells shares for $15,282 By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 26, 2025

Adaptive Biotechnologies’ chief scientific officer sells shares for $15,282 - Investing.com India

Mar 26, 2025
pulisher
Mar 25, 2025

Charles Schwab Investment Management Inc. Acquires 39,831 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Adaptive Biotechnologies stock hits 52-week high at $8.95 By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

Adaptive Biotechnologies stock hits 52-week high at $8.95 - Investing.com

Mar 24, 2025
pulisher
Mar 23, 2025

Amundi Boosts Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up – What’s Next? - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rating Upgraded by The Goldman Sachs Group - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Bank of New York Mellon Corp Has $2.18 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Adaptive Biotechnologies Gains Following Goldman Sachs Upgrade, Share Climb 6% Near Friday Close - MarketScreener

Mar 21, 2025
pulisher
Mar 21, 2025

Analyst Expectations For Adaptive Biotechnologies's Future - Benzinga

Mar 21, 2025
pulisher
Mar 21, 2025

Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday - Benzinga

Mar 21, 2025
pulisher
Mar 21, 2025

Goldman Sachs Upgrades Adaptive Biotechnologies to Buy From Neutral, Adjusts Price Target to $9 From $8 - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Goldman Sachs lifts Adeptus Biotech stock rating to Buy, target to $9 - Investing.com

Mar 21, 2025
pulisher
Mar 20, 2025

Adaptive Biotechnologies (ADPT): Among Stocks Insiders Are Selling In March - Insider Monkey

Mar 20, 2025
pulisher
Mar 17, 2025

10 Stocks Insiders Are Selling In March - Insider Monkey

Mar 17, 2025
pulisher
Mar 14, 2025

Proficio Capital Partners LLC Takes $93,000 Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Critical Survey: Adaptive Biotechnologies (NASDAQ:ADPT) vs. Beam Therapeutics (NASDAQ:BEAM) - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Adaptive Biotechnologies director sells shares worth $70,500 By Investing.com - Investing.com Canada

Mar 12, 2025
pulisher
Mar 12, 2025

Adaptive Biotechnologies director sells shares worth $70,500 - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Adaptive Biotechnologies director sells shares worth $402,270 - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Adaptive Biotechnologies Executives Sell Shares - TradingView

Mar 12, 2025
pulisher
Mar 12, 2025

Minimal Residual Disease Market Expected to rise, 2032 | Adaptive Biotechnologies, Bristol-Myers Squibb Company, Natera, Kite Pharma, Amgen Inc., expected to boost the market - Barchart

Mar 12, 2025
pulisher
Mar 11, 2025

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

US Bancorp DE Sells 43,819 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Revolutionary 7x Sensitivity Boost: Adaptive's New Cancer Detection Test Transforms Lymphoma Monitoring - Stock Titan

Mar 11, 2025
pulisher
Mar 09, 2025

Insider Selling: Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Sells $819,109.98 in Stock - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5% on Insider Selling - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Adaptive Biotechnologies director sells $124,372 in stock By Investing.com - Investing.com Australia

Mar 08, 2025
pulisher
Mar 07, 2025

Adaptive Biotechnologies CEO Chad Robins sells $1.6 million in stock By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Adaptive Biotechnologies’ chief commercial officer Sharon Benzeno sells $311,792 in stock By Investing.com - Investing.com South Africa

Mar 07, 2025

Adaptive Biotechnologies Corp Stock (ADPT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$19.80
price down icon 1.75%
$70.30
price up icon 2.22%
$32.51
price up icon 0.87%
$26.24
price up icon 1.84%
$102.53
price down icon 0.01%
biotechnology ONC
$248.35
price up icon 8.46%
Cap:     |  Volume (24h):